Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 19/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637736 | 0.93 | ADORA2B (0.42) | ADORA2BMAPK1HTT | |
| SCHEMBL16637697 | 0.89 | ADORA2B (0.34) | ADORA2B | |
| SCHEMBL16637503 | 0.88 | ADORA2B (0.46) | ADORA2B | |
| SCHEMBL16637662 | 0.88 | ADORA2B (0.47) | ADORA2B | |
| SCHEMBL16637701 | 0.87 | ADORA2B (0.45) | ADORA2BMAPK1HTT | |
| SCHEMBL19611076 | 0.86 | ADORA2B (0.39) | ADORA2BMAPK1HTT | |
| SCHEMBL16644083 | 0.82 | ADORA2B (0.42) | ADORA2BMAPK1HTT | |
| SCHEMBL16637443 | 0.81 | ADORA2B (0.49) | ADORA2BMAPK1HTT | |
| SCHEMBL19611091 | 0.80 | ADORA2B (0.53) | ADORA2B | |
| SCHEMBL16637734 | 0.80 | ADORA2B (0.43) | ADORA2BMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3055313-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |